Asset profile
Tiotropium bromide
Small molecule
Evidence outlook
Approved: Asthma, Chronic Obstructive Pulmonary Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
102 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 91 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tiotropium Bromide: this drug | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Umeclidinium (Incruse Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), M3 muscarinic acetylcholine receptor | ||
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Ba253BINEB | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Ipratropium | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| PT001 | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor |
…and 87 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
January 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.